Yongjun Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yongjun Zhu has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Li Yang
Department of Internal Medicine, Brody School of Medicine, East Carolina University, Greenville, NC 27834, USA
2 shared publications Xiaoze Wang
Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, People’s Republic of China
2 shared publications- Xuefeng Luo
Department of Gastroenterology and Hepatology Sichuan University‐University of Oxford Huaxi Joint Centre for Gastrointestinal Cancer West China Hospital Sichuan University Chengdu Sichuan China
2 shared publications Fang Yang
Department of Intensive Care Medicine, Chengdu Fifth People’s Hospital, Chengdu, China
1 shared publicationGuo-Xiang Wang
Department of Intensive Care Medicine, Chengdu Fifth People’s Hospital, Chengdu, China
1 shared publicationJing Zhang
Department of Intensive Care Medicine, Chengdu Fifth People’s Hospital, Chengdu, China
1 shared publication
Latest Publications
- 5 March 2021
- Published by Galenos Yayinevi in Diagnostic and Interventional Radiology
- Vol. 27 (2) , 238-243
Combined Y-configured stents for revising occluded transjugular intrahepatic portosystemic shunt
PURPOSE We aimed to determine the technical feasibility, safety and prognosis of the transjugular intrahepatic portosystemic shunt (TIPS) revision by combined Y-configured stents placement. METHODS We retrospectively evaluated 12 patients who received TIPS revision using Y-stenting technique between June 2015 and January 2019. The rates of technical success, complication, shunt patency, hepatic encephalopathy and mortality were described and analyzed. RESULTS The combined Y-configured stents were successfully placed in 11 of 12 patients (92%) without major complications. The median portosystemic pressure gradient (PPG) decreased from 23 mmHg (interquartile range, IQR, 18.5-27.5 mmHg) to 10 mmHg (IQR, 9-14 mmHg). The left internal jugular vein approach was used in 5 patients. Four patients required a shunt extension with an extra stent to resolve the stenosis at the portal venous terminus. Two patients developed hepatic encephalopathy, which was medically controlled within 3 months after the procedure. The TIPS patency and survival rates were both 100% during a median follow-up period of 10 months (IQR, 5.5-14 months). CONCLUSION TIPS revision by combined Y-configured stents placement was technically feasible and safe with favorable clinical outcomes.
- 5 March 2021
- Published by Galenos Yayinevi in Diagnostic and Interventional Radiology
- Vol. 27 (2) , 238-243
Combined Y-configured stents for revising occluded transjugular intrahepatic portosystemic shunt
PURPOSE We aimed to determine the technical feasibility, safety and prognosis of the transjugular intrahepatic portosystemic shunt (TIPS) revision by combined Y-configured stents placement. METHODS We retrospectively evaluated 12 patients who received TIPS revision using Y-stenting technique between June 2015 and January 2019. The rates of technical success, complication, shunt patency, hepatic encephalopathy and mortality were described and analyzed. RESULTS The combined Y-configured stents were successfully placed in 11 of 12 patients (92%) without major complications. The median portosystemic pressure gradient (PPG) decreased from 23 mmHg (interquartile range, IQR, 18.5-27.5 mmHg) to 10 mmHg (IQR, 9-14 mmHg). The left internal jugular vein approach was used in 5 patients. Four patients required a shunt extension with an extra stent to resolve the stenosis at the portal venous terminus. Two patients developed hepatic encephalopathy, which was medically controlled within 3 months after the procedure. The TIPS patency and survival rates were both 100% during a median follow-up period of 10 months (IQR, 5.5-14 months). CONCLUSION TIPS revision by combined Y-configured stents placement was technically feasible and safe with favorable clinical outcomes.
- 11 February 2021
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 67 (2) , 667-675
Pulmonary Artery Catheter in Patients with Severe Acute Pancreatitis: A Single-Center Retrospective Study
Objective It is still uncertain what effects pulmonary artery catheter (PAC)-guided resuscitation has on outcomes for patients with severe acute pancreatitis (SAP). Therefore, we aimed to investigate the effect of PAC on hospital mortality in patients with SAP. Methods We collected the data of patients with a diagnosis of SAP from January 10, 2017, to July 30, 2019. Patients were divided into a PAC group and a control group. The primary outcome measured was the day-28 mortality. Secondary outcomes included day-90 mortality, duration of ICU and hospital stay, ventilation days, usage of renal support and vasoactive agents, incidences of acute abdominal compartment syndrome, infusion volumes, and fluid balance and hemodynamic characteristics measured by the PAC. Kaplan–Meier analysis was applied to estimate survival outcomes. Complications related to PAC were also analyzed. Results There was no significant difference between the PAC group and the control group for day-28 mortality (22.7% vs. 30%, odds ratio, 0.69; 95% CI 0.31–1.52; P = 0.35). The duration of ICU stay in the PAC group was shorter (P = 0.00), and the rate of dependence on renal support treatment was lower in the PAC group than in the control group (P = 0.03). There was no difference in other secondary outcomes and no significant difference in the survival curve between the two groups (log-rank P = 0.72, X2 = 0.13). However, SAP patients inserted PAC within 24 h ICU admission showed that duration of renal support therapy in PAC patients within 24 h ICU admission (mean days, 1.60; standard deviation, 0.14) was shorter than those with 24–72 h ICU admission (mean days, 2.94; standard deviation, 0.73; P = 0.03). The organ failure rates (1 organ, 2 organs and 3 organs) were all lower in PAC patients within 24 h ICU admission than with 24–72 h ICU admission (P = 0.02, P = 0.02, P = 0.048, respectively). Conclusion In patients with severe acute pancreatitis, PAC-guided fluid resuscitation shortened the duration of ICU stay, and patients in the PAC group had a lower rate of dependence on renal support, while no benefit in terms of mortality was observed. However, SAP patients inserted PAC within 24 h ICU admission showed shorter duration of renal support therapy and lower organ failure rates than those with 24–72 h ICU admission, indicating that early use of PAC, especially within 24 h, might be better for SAP patients.
- 11 February 2021
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 67 (2) , 667-675
Pulmonary Artery Catheter in Patients with Severe Acute Pancreatitis: A Single-Center Retrospective Study
Objective It is still uncertain what effects pulmonary artery catheter (PAC)-guided resuscitation has on outcomes for patients with severe acute pancreatitis (SAP). Therefore, we aimed to investigate the effect of PAC on hospital mortality in patients with SAP. Methods We collected the data of patients with a diagnosis of SAP from January 10, 2017, to July 30, 2019. Patients were divided into a PAC group and a control group. The primary outcome measured was the day-28 mortality. Secondary outcomes included day-90 mortality, duration of ICU and hospital stay, ventilation days, usage of renal support and vasoactive agents, incidences of acute abdominal compartment syndrome, infusion volumes, and fluid balance and hemodynamic characteristics measured by the PAC. Kaplan–Meier analysis was applied to estimate survival outcomes. Complications related to PAC were also analyzed. Results There was no significant difference between the PAC group and the control group for day-28 mortality (22.7% vs. 30%, odds ratio, 0.69; 95% CI 0.31–1.52; P = 0.35). The duration of ICU stay in the PAC group was shorter (P = 0.00), and the rate of dependence on renal support treatment was lower in the PAC group than in the control group (P = 0.03). There was no difference in other secondary outcomes and no significant difference in the survival curve between the two groups (log-rank P = 0.72, X2 = 0.13). However, SAP patients inserted PAC within 24 h ICU admission showed that duration of renal support therapy in PAC patients within 24 h ICU admission (mean days, 1.60; standard deviation, 0.14) was shorter than those with 24–72 h ICU admission (mean days, 2.94; standard deviation, 0.73; P = 0.03). The organ failure rates (1 organ, 2 organs and 3 organs) were all lower in PAC patients within 24 h ICU admission than with 24–72 h ICU admission (P = 0.02, P = 0.02, P = 0.048, respectively). Conclusion In patients with severe acute pancreatitis, PAC-guided fluid resuscitation shortened the duration of ICU stay, and patients in the PAC group had a lower rate of dependence on renal support, while no benefit in terms of mortality was observed. However, SAP patients inserted PAC within 24 h ICU admission showed shorter duration of renal support therapy and lower organ failure rates than those with 24–72 h ICU admission, indicating that early use of PAC, especially within 24 h, might be better for SAP patients.
- Open Access
- 12 January 2021
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 66 (12) , 4518-4524
Development and Validation of an Easy-to-Use Risk Scoring System for Screening High-Risk Varices in Patients with HBV-Related Compensated Advanced Chronic Liver Disease
Background A large portion of patients with compensated advanced chronic liver disease (cACLD) do not have varices or only have low risk varices. Aims To create and validate an easy-to-use risk scoring system to identify high-risk varices (HRV) and spare esophagogastroduodenoscopy (EGD) in patients with hepatitis B virus (HBV)-related cACLD. Methods In total, 334 patients with HBV-related cACLD who had undergone routine laboratory tests and ultrasound examination were enrolled. Multivariate logistic regression analysis was used to determine which variables were the independent risk factors for the presence of HRV, so as to establish the scoring system for screening HRV. The criteria were tested in a training cohort with 221 patients and validated in a validation cohort with 113 patients. Results In the training cohort, the prevalence of HRV was 29.5%. Albumin (ALB) [OR 0.83; 95% confidence index (CI) 0.77–0.90; P < 0.0001], platelet count (PLT) (OR 0.96, 95% CI 0.96–0.99; P < 0.0001) and portal vein diameter (OR 1.40; 95% CI 1.15–1.71; P = 0.001) were independent risk factors for the presence of HRV. The negative predictive value was > 95%, when albumin-platelet-portal vein diameter varices scores (APP score) were < 0.24. One hundred twenty-five of 221 (56.6%) patients met an APP score < 0.24 with a 4.8% HRV miss rate. In the validation cohort, 59 of 113 (51.3%) patients met the APP score < 0.24 with a 1.7% HRV miss rate. Conclusions APP score is a potential model for safely screening HRV and sparing EGDs in patients with HBV-related cACLD.
- 12 January 2021
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 66 (12) , 4518-4524
Open AccessDevelopment and Validation of an Easy-to-Use Risk Scoring System for Screening High-Risk Varices in Patients with HBV-Related Compensated Advanced Chronic Liver Disease
Background A large portion of patients with compensated advanced chronic liver disease (cACLD) do not have varices or only have low risk varices. Aims To create and validate an easy-to-use risk scoring system to identify high-risk varices (HRV) and spare esophagogastroduodenoscopy (EGD) in patients with hepatitis B virus (HBV)-related cACLD. Methods In total, 334 patients with HBV-related cACLD who had undergone routine laboratory tests and ultrasound examination were enrolled. Multivariate logistic regression analysis was used to determine which variables were the independent risk factors for the presence of HRV, so as to establish the scoring system for screening HRV. The criteria were tested in a training cohort with 221 patients and validated in a validation cohort with 113 patients. Results In the training cohort, the prevalence of HRV was 29.5%. Albumin (ALB) [OR 0.83; 95% confidence index (CI) 0.77–0.90; P < 0.0001], platelet count (PLT) (OR 0.96, 95% CI 0.96–0.99; P < 0.0001) and portal vein diameter (OR 1.40; 95% CI 1.15–1.71; P = 0.001) were independent risk factors for the presence of HRV. The negative predictive value was > 95%, when albumin-platelet-portal vein diameter varices scores (APP score) were < 0.24. One hundred twenty-five of 221 (56.6%) patients met an APP score < 0.24 with a 4.8% HRV miss rate. In the validation cohort, 59 of 113 (51.3%) patients met the APP score < 0.24 with a 1.7% HRV miss rate. Conclusions APP score is a potential model for safely screening HRV and sparing EGDs in patients with HBV-related cACLD.
- 1 November 2019
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 23 (11) , 2193-2200
Emergency Transjugular Intrahepatic Portosystemic Shunt: an Effective and Safe Treatment for Uncontrolled Variceal Bleeding
- 1 November 2019
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 23 (11) , 2193-2200
Emergency Transjugular Intrahepatic Portosystemic Shunt: an Effective and Safe Treatment for Uncontrolled Variceal Bleeding